Cytokines as new treatment targets in chronic heart failure

Current Controlled Trials in Cardiovascular Medicine

Volumn 2, Issue 6, 2001, Pages 271-277

  Damås, Jan Kristian ^a   Gullestad, Lars ^b   Aukrust, Pål ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

Chronic heart failure; Cytokines; Immunomodulating therapy; Intravenous immunoglobulin

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CYTOKINE; CYTOKINE ANTIBODY; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETANERCEPT; IMMUNOGLOBULIN; METOPROLOL; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TARGETING; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HUMAN; IMMUNOMODULATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SIDE EFFECT;

EID: 0035700565     PISSN: 14686708     EISSN: None     Source Type: Journal    
DOI: 10.1186/CVM-2-6-271     Document Type: Review

References (72)

1. Effect of vasodilator therapy on mortality in chronic heart failure. Results of a Veterans Administration cooperative study (V-HeFT)
2. Effect of milrinone on mortality in severe heart failure
3. Effects of enalapril on mortality in severe congestive heart failure
4. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators (RALES)
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
6. CIBIS-II Investigators and Commitee: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
7. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
8. Innate immunity
9. Unraveling function in the TNF ligand and receptor families
10. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
11. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
12. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension
13. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)
14. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
15. Elevated circulating levels of C-C chemokines in patients with congestive heart failure
16. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes
17. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart
18. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure
19. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure
20. Myocardial gene expression of leukemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure
21. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha
22. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive dysfunction and remodelling in rats
23. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the mammalian heart
24. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness
25. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
26. Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes
27. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes
28. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress
29. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes
30. Cytokines and cardiomyocyte death
31. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy
32. The role of inflammation and infection in coronary artery disease
33. Chlamydia infections and heart disease linked through antigenic mimicry
34. Molecular mimicry, anti-coxackievirus B3 neutralizing monoclonal antibodies, and myocarditis
35. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
36. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells
37. The role of oxidative stress in the genesis of heart disease
38. Is the NF-κB the sensor of oxidative stress?
39. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients
40. A dose-dependent increase in mortality with vesnarinone among patents with severe heart failure. Vesnarinone Trial Investigators
41. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST)
42. Role of cytokines in the mechanism of action of amlodipine: The PRAISE heart failure trial
43. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure
44. Angiotensin-converting enzyme inhibition prevents arterial factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of accelerated atherosclerosis
45. Angiotensin-converting enzyme inhibitin reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction
46. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial fibrosis after acute myocardial infarction
47. Propranolol treatment affects parameters of human immunity
48. Beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling
49. Effects of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy
50. Effect of metoprolol on cytokine levels in chronic heart failure: A substudy in the MERIT-HF trial
51. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
52. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
53. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure
54. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
55. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy
56. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol
57. New therapies for heart failure: Is thalidomide the answer?
58. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure
59. Treatment of experimental viral myocarditis with interleukin-10
60. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat
61. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effects of intravenous immunoglobulin
62. Effects of soluble TNF receptor treatment on lipopolysaccaride-induced myocardial cytokine expression
63. Clinical trials update
64. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases
65. Intravenous immunoglobins in the therapy of autoimmune and systemic inflammatory disorders
66. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy
67. Intravenous immune globulin in the therapy of peripartum cardiomyopathy
68. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy
69. Immunomodulatory effect of immunoglobulins
70. Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: Has the time come for randomized clinical trials
71. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption
72. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution